Evolutec Ltd.
This article was originally published in Start Up
Executive Summary
Evolutec Ltd.'s drug discovery program harnesses the power of blood-sucking ticks and other ectoparasites-many of which can feed for weeks undetected by their host's immune system-to discover drug candidates for inflammatory and autoimmune diseases, anticoagulation, cardiovascular diseases and oncology.